Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
| Aktionär | Typ | Gehalten (Tatsächlich) | % Ausstehender Aktien | Marktwert | Positionsdatum |
|---|---|---|---|---|---|
| Morgan Stanley Investment Management Inc. | Institution | 9.442.785 | 10,01% | US$ 37,68M | 2026-03-31 |
| Empery Asset Management, LP | Institution | 8.944.118 | 9,48% | US$ 35,69M | 2026-03-31 |
| FMR LLC | Institution | 8.103.400 | 8,59% | US$ 32,33M | 2026-03-31 |
| Bain Capital Life Sciences Investors, LLC | Institution | 7.967.454 | 8,45% | US$ 31,79M | 2026-03-31 |
| Perceptive Advisors LLC | Institution | 6.737.648 | 7,14% | US$ 26,88M | 2026-03-31 |
| Perceptive Life Sciences Master Fund, Ltd. | Institution | 6.737.648 | 7,14% | US$ 26,88M | 2026-03-31 |
| Saturn V Capital Management LP | Institution | 6.456.646 | 6,85% | US$ 25,76M | 2026-03-31 |
| Deep Track Capital, LP | Institution | 6.339.535 | 6,72% | US$ 25,29M | 2026-03-31 |
| Kalehua Capital Management LLC | Institution | 3.722.840 | 3,95% | US$ 14,85M | 2026-03-31 |
| Vanguard Capital Management, LLC | Institution | 3.497.612 | 3,71% | US$ 13,96M | 2026-03-31 |
| Braidwell LP | Institution | 3.272.954 | 3,47% | US$ 13,06M | 2026-03-31 |
| NEA 18 Venture Growth Equity, L.P. | Institution | 3.233.744 | 3,43% | US$ 12,90M | 2025-10-27 |
| New Enterprise Associates, Inc. | Institution | 3.233.743 | 3,43% | US$ 12,90M | 2026-03-31 |
| Rosalind Advisors, Inc. | Institution | 3.214.766 | 3,41% | US$ 12,83M | 2026-03-31 |
| Blackstone Alternative Asset Management L.P. | Institution | 2.681.922 | 2,84% | US$ 10,70M | 2026-03-31 |
| Trails Edge Capital Partners, LP | Institution | 2.571.478 | 2,73% | US$ 10,26M | 2026-03-31 |
| Nantahala Capital Management, LLC | Institution | 2.449.468 | 2,60% | US$ 9,77M | 2026-03-31 |
| BVF Partners L.P. | Institution | 2.233.742 | 2,37% | US$ 8,91M | 2026-03-31 |
| Samsara BioCapital LLC | Institution | 1.832.566 | 1,94% | US$ 7,31M | 2026-03-31 |
| BlackRock, Inc. | Institution | 1.211.794 | 1,28% | US$ 4,84M | 2026-03-31 |
| Millennium Management LLC | Institution | 1.210.514 | 1,28% | US$ 4,83M | 2026-03-31 |
| Biotechnology Value Fund L.P. | Institution | 1.158.732 | 1,23% | US$ 4,62M | 2025-08-20 |
| Woodline Partners LP | Institution | 1.001.095 | 1,06% | US$ 3,99M | 2026-03-31 |
| Susquehanna International Group, LLP | Institution | 958.821 | 1,02% | US$ 3,83M | 2026-03-31 |
| Geode Capital Management, LLC | Institution | 939.726 | 1,00% | US$ 3,75M | 2026-03-31 |
| Biotechnology Value Fund II, L.P. | Institution | 906.855 | 0,96% | US$ 3,62M | 2025-08-20 |
| The Goldman Sachs Group, Inc. | Institution | 882.134 | 0,94% | US$ 3,52M | 2026-03-31 |
| Dr. Christophe Arbet-Engels | Insider | 864.207 | 0,92% | US$ 3,45M | 2025-02-12 |
| StemPoint Capital LP | Institution | 850.742 | 0,90% | US$ 3,39M | 2026-03-31 |
| Bain Capital Life Sciences Fund II, L.P. | Institution | 607.832 | 0,64% | US$ 2,43M | 2025-12-31 |
| Dr. Mary DiBiase | Insider | 490.980 | 0,52% | US$ 1,96M | 2025-02-12 |
| Vanguard Fiduciary Trust Company | Institution | 480.733 | 0,51% | US$ 1,92M | 2026-03-31 |
| State Street Global Advisors, Inc. | Institution | 403.534 | 0,43% | US$ 1,61M | 2026-03-31 |
| Dr. Arthur Taveras | Insider | 388.026 | 0,41% | US$ 1,55M | 2024-10-07 |
| Marshall Wace LLP | Institution | 336.834 | 0,36% | US$ 1,34M | 2026-03-31 |
| Stonepine Capital Management LLC | Institution | 335.309 | 0,36% | US$ 1,34M | 2026-03-31 |
| VR Management, LLC | Institution | 330.525 | 0,35% | US$ 1,32M | 2026-03-31 |
| UBS Asset Management AG | Institution | 267.340 | 0,28% | US$ 1,07M | 2026-03-31 |
| Acorn Bioventures | Institution | 234.039 | 0,25% | US$ 933,82k | 2026-03-31 |
| Qube Research & Technologies Ltd | Institution | 218.954 | 0,23% | US$ 873,63k | 2026-03-31 |
| Northern Trust Global Investments | Institution | 178.235 | 0,19% | US$ 711,16k | 2026-03-31 |
| Pale Fire Capital SE | Institution | 167.590 | 0,18% | US$ 668,68k | 2026-03-31 |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
